Xenon Pharmaceuticals
XENEPre-clinicalXenon Pharmaceuticals is a Canadian biotech pioneer utilizing human genetics to identify and validate novel drug targets, primarily within the ion channel space, for the treatment of neurological and other disorders. Its most advanced asset, XEN1101, a Kv7 potassium channel opener, has demonstrated positive Phase 2b results in major depressive disorder (MDD) and focal onset seizures, positioning it for pivotal Phase 3 trials. The company's strategy combines internal development of its core pipeline with strategic collaborations, such as its ongoing partnership with Neurocrine Biosciences, to advance its genetic discovery platform and expand its therapeutic reach.
XENE · Stock Price
Historical price data
AI Company Overview
Xenon Pharmaceuticals is a Canadian biotech pioneer utilizing human genetics to identify and validate novel drug targets, primarily within the ion channel space, for the treatment of neurological and other disorders. Its most advanced asset, XEN1101, a Kv7 potassium channel opener, has demonstrated positive Phase 2b results in major depressive disorder (MDD) and focal onset seizures, positioning it for pivotal Phase 3 trials. The company's strategy combines internal development of its core pipeline with strategic collaborations, such as its ongoing partnership with Neurocrine Biosciences, to advance its genetic discovery platform and expand its therapeutic reach.
Technology Platform
A proprietary human genetics platform that identifies and validates novel drug targets by studying individuals with extreme disease phenotypes, with a focus on ion channel targets for neurological disorders.
Pipeline Snapshot
2323 drugs in pipeline, 11 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| Azetukalner + Placebo | Bipolar Disorder | Phase 3 |
| Azetukalner + Placebo | Major Depressive Disorder | Phase 3 |
| Azetukalner | Major Depressive Disorder | Phase 3 |
| XEN1101 + Placebo | Primary Generalized Tonic-Clonic Seizures | Phase 3 |
| Azetukalner | Bipolar Depression | Phase 3 |
Funding History
4Total raised: $270M
Opportunities
Risk Factors
Competitive Landscape
Xenon competes with large pharma neurology leaders (e.g., UCB, Jazz) and other biotechs in MDD and epilepsy. Its key differentiation is the novel Kv7 potassium channel mechanism of XEN1101 and its foundational human genetics platform, which de-risks target discovery. However, commercial execution against established players remains a future hurdle.
Company Info
Trading
Contact
Therapeutic Areas
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile